This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gardell, S. J. Search for Related Content PubMed PubMed Citation Articles by Gardell, S. J. Social Bookmarking                         What's this?

The Search for the Ideal Thrombolytic Agent: Maximize the Benefit and Minimize the Risk

Department of Biological Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486

Streptokinase, acylated plasminogen streptokinase complex, and tissue-type plasminogen activator (tPA) are widely used for the treatment of acute myocardial infarction. These thrombolytic agents restore blood flow in occluded coronary arteries, salvage myocardial function, and decrease mortality. The success of thrombolytic therapy depends on the prompt and stable recanalization of the occluded blood vessel. Hemorrhagic events undermine the safety of fibrinolytic agents. Most bleeding complications occur at vascular puncture sites and can be avoided by limiting invasive procedures; however, an increased incidence of devastating intracranial bleeds is also encountered. The cause of thrombolytic-induced intracranial hemorrhage is unknown but may be due to lysis of protective hemostatic plugs. Another potential contributor to bleeding is activation of circulating plasminogen by the exogenous plasminogen activator to yield fluid-phase plasmin. Plasmin is a promiscuous proteinase that degrades many proteins that play pivotal roles in hemostasis and the integrity of the microvasculature. Tissue-type plasminogen activator activity is depressed in the absence of fibrin; hence, its use as a thrombolytic agent was anticipated to avoid the untoward consequences of plasminemia. However, the administration of pharmacologic doses of tPA can result in the activation of appreciable quantities of circulating plasminogen. In contrast to currently available thrombolytic agents, the activity of the vampire bat salivary plasminogen activator (BatPA) displays a strict requirement for the presence of fibrin. Assessment of BatPA using animal models of arterial thrombosis has demonstrated efficacy but without activation of systemic plasminogen. The avoidance of plasminemia when using BatPA as a fibrinolytic agent may circumvent bleeding complications that can compromise the safety of thrombolytic therapy.

Key Words: Thrombolysis • plasminogen activator • fibrinolytic therapy • acute myocardial infarction

• AIMS Trial Study Group ( 1988). Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1: 545-549.[Medline] [Order article via Infotrieve]
• Arnold AER, Bowr RW, Collen D., van Es G-A., Lubsen J., Serruys PW, Simoons ML, and Verstraete M., for the European Co-operative Study Group for rt-PA (1989). Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. J. Am. Coll. Cardiol. 14: 581-588.[Abstract]
• Bennett WF, Paoni NF, Keyt BA, Botstein D., Jones AJS, Presta L., Wurm FM, and Zoller MJ (1991). High resolution analysis of functional determinants on human tissue-type plasminogen activator. J. Biol. Chem. 266: 5191-5201.[Abstract/Free Full Text]
• Bergum PW and Gardell SJ (1992). Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor unlike human tissue-type plasminogen activator: A kinetic analysis. J. Biol. Chem. 267: 17726-17731.[Abstract/Free Full Text]
• Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M., Collen D., Feit F., Gore JM, Hillis D., Lam-brew CT, Leiboff R., Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G., Tracy RT, and Chesebro JH, for the TIMI Investigators (1991 ). Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann. Int. Med. 115: 256-265.[Abstract/Free Full Text]
• Califf RM, Fortin DF, Tenaglia AN, and Sane DC (1992). Clinical risks of thrombolytic therapy. Am. J. Cardiol. 69: 12A-20A.[Medline] [Order article via Infotrieve]
• Camiolo SM, Thorsen S., and Astrup T. (1971). Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc. Soc. Exp. Biol. Med. 138: 277-280.[CrossRef][Medline] [Order article via Infotrieve]
• Chesebro JH, Knatterud G., Roberts R., Borer J., Cohen LS, Dalen J., Dodge HT, Francis CK, Hillis D., Ludbrook P., Markis JE, Mueller H., Passamani ER, Powers ER, Rao AK, Robertson T., Ross A., Ryan TJ, Sobel BE, Willerson J., Williams DO, Zaret BL, and Braunwald E. (1987). Thrombolysis in myocardial infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76: 142-154.[Abstract/Free Full Text]
• Collen D. and Lijnen HR (1991). Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78: 3114-3124.[Free Full Text]
• Cragg DR, Friedman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, Timmis GC, O'Neill WW, and Schreiber TL (1991). Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann. Intern. Med. 115: 173-177.[Abstract/Free Full Text]
• De Jaegere PP, Arnold AA, Balk AH, and Simoons ML (1992). Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors. JACC 19: 289-294.[Abstract]
• DeWood MA, Spores J., Notske R., Mouser LT, Bur-roughs R., Golden MS, and Lang HT (1980). Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303:897-902.[Abstract]
• Eisenberg PR, Sobel BE, and Jaffe AS (1992). Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. JACC 19: 1065-1069.[Abstract]
• Fennerty AG, Levine MN, and Hirsh J. (1989). Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 95: 88S-97S.[Medline] [Order article via Infotrieve]
• Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, and Friedman PA (1989). Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J. Biol. Chem. 264: 17947-17952.[Abstract/Free Full Text]
• Gardell SJ, Hare TR, Bergum PW, Cuca GC, O'Neill-Palladino L., and Zavodny SM (1990). Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 12: 2560-2564.
• Gardell SJ, Ramji DR, Stabilito II, Fujita T., Lynch JJ, Cuca GC, Jain D., Wang S., Tung J., Mark GE, and Shebuski RJ (1991). Effective thrombolysis without marked plasminemia following bolus intravenous administration of a vampire bat salivary plasminogen activator in rabbits. Circulation 84: 244-253.[Abstract/Free Full Text]
• Giles AR, Tinlin S., and Greenwood R. (1982). A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60: 727-730.[Abstract/Free Full Text]
• Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W., Yasuda T., Johns JA, Ziskind AA, Finkelstein D., and Collen D. (1989). Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 80: 581-588.[Abstract/Free Full Text]
• Gruppo Italiano per lo studio della streptochinasi nell'infarto miocardico (1986). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1: 397-401.[CrossRef][Medline] [Order article via Infotrieve]
• Gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico (1990). GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 336: 65-70.[Web of Science][Medline] [Order article via Infotrieve]
• Haber E., Quertermous T., Matsueda GR, and Runge MS (1989). Innovative approaches to plasminogen activator therapy. Science 243: 51-56.[Abstract/Free Full Text]
• Hajjar KA and Hamel NM (1990). Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J. Biol. Chem. 265: 2908-2916.[Abstract/Free Full Text]
• Hajjar KA, Hamel NM, Harpel PC, and Nachman RL (1987). Binding of tissue plasminogen activator to cultured human endothelial cells. J. Clin. Invest. 80:1712-1719.[Web of Science][Medline] [Order article via Infotrieve]
• Hare TR and Gardell SJ (1992). Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation. Thromb. Haemost. 68: 165-169.[Web of Science][Medline] [Order article via Infotrieve]
• Higgins DL and Bennett WF (1990). Tissue plasminogen activator: The biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev. Pharmacol. Toxicol. 30: 91-121.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hoylaerts M., Rijken DC, Lijnen HR, and Collen D. (1982). Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J. Biol. Chem. 257: 2912-2919.[Abstract/Free Full Text]
• The International Study Group (1990). In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 336: 71-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2: 349-360.[Medline] [Order article via Infotrieve]
• ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992). ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 339: 753-770.[Web of Science][Medline] [Order article via Infotrieve]
• Lijnen HR and Collen D. (1991). Strategies for the improvement of thrombolytic agents. Thromb. Haemost. 66: 88-110.[Web of Science][Medline] [Order article via Infotrieve]
• Lind SE (1991). The bleeding time does not predict surgical bleeding. Blood 77: 2547-2552.[Free Full Text]
• Magnani B., for the PAIMS investigators (1989 ). Plasminogen activator Italian multicenter study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J. Am. Coll. Cardiol. 13: 19-26.[Abstract]
• Mellott MJ, Stabilito II, Holahan MA, Cuca GC, Wang S., Li P., Barrett JS, Lynch JJ, and Gardell SJ (1992). Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscl. Thromb. 12: 212-221.[Abstract/Free Full Text]
• Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and TAMI Study Group (1990). Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781-791.[Abstract/Free Full Text]
• Pennica D., Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E., Seeburg PH, Heyneker HL, Goeddel DV, and Collen D. (1983). Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (London ) 301:214-221.[CrossRef][Medline] [Order article via Infotrieve]
• Rao AK, Pratt C., Berke A., Jaffe A., Ockene I., Schreiber TL, Bell WR, Knatterud G., Robertson TL, and Terrin ML, for the TIMI investigators (1988 ). Thrombolysis in myocardial infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am. Coll. Cardiol. 11: 1-11.[Abstract]
• Rodgers RPC and Levin J. (1990). A critical reappraisal of the bleeding time. Semin. Thromb. Hemostasis 16: 1-20.[Web of Science][Medline] [Order article via Infotrieve]
• Rudd MA, Johnstone MT, Rabbani LE, George D., Ware JA, and Loscalzo J. (1991). Thrombolytic therapy causes an increase in vascular permeability that is reversed by 1-deamino-8-D-vasopressin. Circulation 84: 2568-2573.[Abstract/Free Full Text]
• Sherry S. and Marder VJ (1991). Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction. Ann. Intern. Med. 114: 417-423.[Abstract/Free Full Text]
• Sloan MA and Gore JM (1992). Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am. J. Cardiol. 69: 21A-38A.
• Stump DC, Califf RM, Topol EJ, Sigmon K., Thorn-ton D., Masek R., Anderson L., Collen D., TAMI study group (1989). Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 80: 1222-1230.[Abstract/Free Full Text]
• Topol EJ (1990). Ultrathrombolysis. J. Am. Coll. Cardiol. 15: 922-924.[Web of Science][Medline] [Order article via Infotrieve]
• Torr SR, Nachowiak DA, Fujii S., and Sobel BE (1992). "Plasminogen steal" and clot lysis. JACC 19: 1085-1090.[Abstract]
• Tracy RP and Bovill EG (1992). Fibrinolytic parameters and hemostatic monitoring: Identifying and predicting patients at risk for major hemorrhagic events. Am. J. Cardiol. 69: 52A-59A.[CrossRef][Medline] [Order article via Infotrieve]
• Verstraete M., Bernard R., Bory M., Brower RW, Collen D., de Bono DP, Erbel R., Huhmann W., Lennane RJ, Lubsen J., Mathey D., Meyer J., Michels HR, Rutsch W., Schartl M., Schmidt W., Uebis R., and von Essen R. (1985). Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1: 842-847.[Web of Science][Medline] [Order article via Infotrieve]
• White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M., Hart HH, Sharpe DN, Whitlock RML, and Norris RM (1989). Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N. Engl. J. Med. 320: 817-821.[Abstract]
• Wilcox RG, von der Lippe G., Olsson CG, Jenssen G., Skene AM, and Hampton JR (1988). Trial of tissue plasminogen activator (rt-PA) for mortality reduction in acute myocardial infarction: The Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 2: 525-530.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 21, No. 2, 190-198 (1993)
DOI: 10.1177/019262339302100211


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gardell, S. J. Search for Related Content PubMed PubMed Citation Articles by Gardell, S. J. Social Bookmarking                         What's this?